home > drugs a-z list > somavert (pegvisomant) drug center > somavert (pegvisomant) drug - overdosage and contraindications

Somavert

font size

OVERDOSE

In one reported incident of acute overdose with SOMAVERT (pegvisomant) during pre-marketing clinical studies, a patient self-administered 80 mg/day for seven days. The patient experienced a slight increase in fatigue, had no other complaints, and demonstrated no significant clinical laboratory abnormalities. In cases of overdose, administration of SOMAVERT (pegvisomant) should be discontinued and not resumed until IGF-I levels return to within or above the normal range.

Drug Abuse And Dependence

Available data do not demonstrate drug-abuse potential or psychological dependence with SOMAVERT. Radiolabeled pegvisomant does not cross the blood-brain barrier in rats.

CONTRAINDICATIONS

SOMAVERT (pegvisomant) is contraindicated in patients with a history of hypersensitivity to any of its components. The stopper on the vial of SOMAVERT (pegvisomant) contains latex.

Last reviewed on RxList: 8/13/2010
This monograph has been modified to include the generic and brand name in many instances.

Somavert - User Reviews

Somavert User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Somavert sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.